Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Jabil Healthcare Signs Strategic Collaboration Agreement with E3D, Expanding Pharmaceutical Market Offering


Jabil Healthcare, a division of Jabil Inc. (NYSE: JBL), today announced it has entered a strategic collaboration agreement with global drug delivery device company E3D, a member of the Elcam Medical Group, which gives Jabil access to E3D’s reusable mechanical auto-injector. Under the terms of this deal, Jabil has secured exclusive rights to develop a high-volume reusable auto-injector and connected variants.

The agreement enables Jabil Healthcare to further develop connected auto-injectors for a range of dosing volumes and patient-centric benefits, ultimately creating a platform of devices. Jabil Healthcare applies its expertise to help customers through the design, development and manufacture of some of the most complex and innovative drug delivery devices in the market.

“Our collaboration with E3D enhances Jabil’s development of pharmaceutical solutions that move us into the future of connected, digital devices that are more intuitive, economical and sustainable,” said James O’Gorman, vice president, Pharmaceutical Delivery Systems (PDS), Jabil Healthcare. “This is an exciting expansion of our relationship with E3D that will benefit our market offering and healthcare customers alike.”

“As a leader in the healthcare arena, Jabil Healthcare is the perfect partner for us and for a drug delivery market that requires the highest levels of competence, experience and scale in manufacturing,” said Tsachi Shaked, general manager of E3D. “Our complementary expertise in electronics, manufacturing and data analysis is the type of collaboration that should help speed advances and adoption of digital health technologies.”

Jabil Healthcare’s Pharmaceutical Delivery Systems business is relied on by many of the world’s leading healthcare brands to execute large New Product Introductions (NPI) and ramp into commercial production, applying proven manufacturing processes to reduce risk and overall cost. Together, Jabil Healthcare and E3D form a comprehensive offering of pre-launch support, including full global commercial supply, lifecycle management, final product assembly, labeling and legal manufacturing services.

About Jabil

Jabil (NYSE: JBL) is a manufacturing solutions provider with over 260,000 employees across 100 locations in 30 countries. The world's leading brands rely on Jabil's unmatched breadth and depth of end-market experience, technical and design capabilities, manufacturing know-how, supply chain insights and global product management expertise. Driven by a common purpose, Jabil and its people are committed to making a positive impact on their local community and the environment. Visit www.jabil.com to learn more.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210304005104/en/

Jabil Circuit Aktie

103,00 €
0,49 %
Die Jabil Circuit Aktie erlebt heute einen kleinen Anstieg von 0,49 %.
Die Jabil Circuit Aktie erhält mehrere Buy-Einschätzungen, ohne eine Gegenstimme.
Dadurch ergibt sich bei einem Kursziel von 128 € ein positives Potenzial von 24.27% im Vergleich zum aktuellen Kurs von 103.0 € bei Jabil Circuit.
Like: 0
Teilen
Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure. Investor relations, public relations, public policy and marketing professionals rely on Business Wire for secure and accurate distribution of market-moving news and multimedia.

Rechtlicher Hinweis

Kommentare